Literature DB >> 15466829

Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.

Myung Ah Lee1, In Sook Woo, Jin-Hyoung Kang, Young Seon Hong, Kyung Shik Lee.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma is a chemoresistant cancer for which effective chemotherapy is not yet available. We investigated the efficacy and toxicity of the combination of gemcitabine and cisplatin as second-line chemotherapy in four patients with advanced, progressive intrahepatic cholangiocarcinoma.
METHODS: Four patients were enrolled who had previous chemotherapy with epirubicin, cisplatin and protracted infusion of 5-FU. All these patients treated with gemcitabine 1000 mg/m(2) intravenously (i.v.) on days 1 and 8 for 30 min, cisplatin 75 mg/m(2) i.v. on day 1 for 90 min, given every 21 days.
RESULTS: Two patients had partial response (PR), and two had stable disease (SD), with one of the latter showing a decrease in tumor size of 35%. Median time to progression was 5 months (range, 3-9 months) and median survival was 9 months (range, 8-16 months). Toxicity was mild and tolerable.
CONCLUSIONS: Gemcitabine and cisplatin combination chemotherapy may be an effective regimen for advanced intrahepatic cholangiocarcinoma. Further study is warranted to determine the efficacy of this combination regimen.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466829     DOI: 10.1093/jjco/hyh099

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  10 in total

1.  Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Suguru Mizuno; Keisuke Yamamoto; Hiroshi Yagioka; Yoko Yashima; Kazumichi Kawakubo; Hirofumi Kogure; Osamu Togawa; Saburo Matsubara; Yukiko Ito; Naoki Sasahira; Kenji Hirano; Takeshi Tsujino; Nobuo Toda; Minoru Tada; Masao Omata; Kazuhiko Koike
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

2.  A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer.

Authors:  Masako Nishimura
Journal:  World J Hepatol       Date:  2010-05-27

3.  Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Suguru Mizuno; Keisuke Yamamoto; Hiroshi Yagioka; Yoko Yashima; Kazumichi Kawakubo; Hirofumi Kogure; Osamu Togawa; Saburo Matsubara; Naoki Sasahira; Kenji Hirano; Takeshi Tsujino; Minoru Tada; Masao Omata; Kazuhiko Koike
Journal:  Invest New Drugs       Date:  2010-07-06       Impact factor: 3.850

4.  Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.

Authors:  Renato V LaRocca; Matthew D Hicks; Lennea Mull; Brenda Foreman
Journal:  J Gastrointest Cancer       Date:  2007

Review 5.  Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway.

Authors:  Iman W Achkar; Nabeel Abdulrahman; Hend Al-Sulaiti; Jensa Mariam Joseph; Shahab Uddin; Fatima Mraiche
Journal:  J Transl Med       Date:  2018-04-11       Impact factor: 5.531

6.  A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.

Authors:  Kazuma Kobayashi; Akihito Tsuji; Sojiro Morita; Tadashi Horimi; Tetsuhiko Shirasaka; Takashi Kanematsu
Journal:  BMC Cancer       Date:  2006-05-06       Impact factor: 4.430

Review 7.  Current status of chemotherapy for the treatment of advanced biliary tract cancer.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Kazuhiko Koike
Journal:  Korean J Intern Med       Date:  2013-08-14       Impact factor: 2.884

8.  Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.

Authors:  Takashi Okumura; Jun Nakamura; Keita Kai; Yasushi Ide; Hiroaki Nakamura; Hiroki Koga; Takao Ide; Atsushi Miyoshi; Kenji Kitahara; Hirokazu Noshiro
Journal:  World J Surg Oncol       Date:  2014-11-04       Impact factor: 2.754

Review 9.  Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.

Authors:  Rosa B Schmuck; Cynthia V de Carvalho-Fischer; Christopher Neumann; Johann Pratschke; Marcus Bahra
Journal:  Cancer Med       Date:  2015-12-09       Impact factor: 4.452

10.  Inhibition of Ceramide Glycosylation Enhances Cisplatin Sensitivity in Cholangiocarcinoma by Limiting the Activation of the ERK Signaling Pathway.

Authors:  Piyasiri Chueakwon; Peeranat Jatooratthawichot; Krajang Talabnin; James R Ketudat Cairns; Chutima Talabnin
Journal:  Life (Basel)       Date:  2022-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.